Inactive Instrument

Celestial Biolabs Limited

532871

INE221I01017

Celestial Biolabs Limited Announces Demise of Devarakonda Chidvilasa Sastri, Non-Executive Independent Director

April 23, 2024 at 06:48 am

Celestial Biolabs Limited announced the sad demise of Dr. Devarakonda Chidvilasa Sastri, Non-Executive Independent Director of the Company, on 4th April, 2024. However, the same was came to the notice of Company on 22.04.2024.

Latest news about Celestial Biolabs Limited

Celestial Biolabs Limited Announces Demise of Devarakonda Chidvilasa Sastri, Non-Executive Independent Director	04-23	CI
Celestial Biolabs Limited Announces Board Changes	04-22	CI
Celestial Biolabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	03-29	CI
Celestial Biolabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Celestial Biolabs Limited Announces Executive Appointments	22-09-30	CI
Celestial Biolabs Limited Auditor Raises 'Going Concern' Doubt	22-09-05	CI
Celestial Biolabs Limited Auditor Raises 'Going Concern' Doubt	22-09-05	CI
Celestial Biolabs Limited Auditor Raises 'Going Concern' Doubt	22-09-04	CI
Celestial Biolabs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	22-09-02	CI
Celestial Biolabs Limited Announces Chief Financial Officer Changes	22-09-02	CI
Celestial Biolabs Limited Appoints Sada Naga Latha as Company Secretary and Compliance Officer	22-05-16	CI
Celestial Biolabs Limited Announces Change in Registered Office Address	22-04-26	CI
Celestial Biolabs Ltd Announces Resignation of Hardeep Choudhary as Company Secretary and Compliance Officer	19-11-20	CI
Celestial Biolabs Limited Reports Earnings Results for the First Quarter Ended June 30, 2019	19-08-14	CI
Celestial Biolabs Limited Announces Management Appointments	19-06-18	CI
Celestial Biolabs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	19-06-06	CI
Celestial Biolabs Limited Reports Earnings Results for the Third Quarter Ended December 31, 2018	19-02-14	CI
Celestial Biolabs Limited Announces Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended Sept. 30, 2018	18-11-14	CI
Celestial Biolabs Limited announced a financing transaction	18-09-02	CI
Celestial Biolabs Limited Announces Earnings Results for the First Quarter Ended June 30, 2018	18-08-14	CI
Celestial Biolabs Limited Reports Audited Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2018	18-06-01	CI
Celestial Biolabs Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017	18-02-14	CI
Celestial Biolabs Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2017	17-12-14	CI
Celestial Biolabs Limited Announces Unaudited Earnings Results for the First Quarter Ended June 30, 2017	17-09-13	CI
Celestial Biolabs Ltd. Reports Audited Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2017	17-05-30	CI

Chart Celestial Biolabs Limited

Duration

Period

More charts

Company Profile

Celestial Biolabs Limited is an India-based biopharmaceutical company. The Company is engaged in the production and supply of herbal and feed supplement formulations. The Company's products portfolio includes health products for men, women and children. Its product categories include herbal, enzymes and nutraceuticals. Its herbal product category includes products, such as proprietary products and classical products. Its proprietary products include BIOVITA, CADALMIN GAe, CEL-DIGEST, BIOLIV, RHUMACEL, CEL-CLEAR, Trem Plus, O-KOF, BIOPOWER GOLD, BIO-DNORM, DERMACEL, GYNOCEL, HEALTHONE, RELIFIN, and C-KAPS. Its Classical products include Hingwastak Churna, Avipattikar Churna, Lavan Bhaskar Churna, Talishadi Churna, Sitopaladi Churna, Arogyavardhini Vati, Chandraprabha Vati, and Triphala Churna. Its enzymes products include CELZYME-P, CELZYME-L, CELZYME-DMAX, CELZYME-OXI, and CELZYME-TEXDS. Its nutraceuticals products include Psyllium seed husk, Lycopene, Alpha lipoic acid, and Fenugreek.

Sector

Food Processing

Calendar

2024-08-13 - Q1 2025 Earnings Release (Projected)

More about the company

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
ZHEJIANG NHU COMPANY LTD.	+15.09%	8.35B
BELLRING BRANDS, INC.	+3.37%	7.62B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+1.45%	6.01B
THE SIMPLY GOOD FOODS COMPANY	-6.26%	3.75B
BYHEALTH CO., LTD	-9.86%	3.7B
XIAMEN KINGDOMWAY GROUP COMPANY	-6.55%	1.34B
HERBALIFE LTD.	-28.83%	1.13B
SIRIO PHARMA CO., LTD.	+14.31%	992M
USANA HEALTH SCIENCES, INC.	-10.78%	925M

Special Foods & Wellbeing Products